Consensus $10.19. Narrows FY25 revenue view to down 0.5%-1.5% from down 0.5%-2.5%. “In this environment, we believe it is critical to remain intently focused on our strategy to further differentiate ourselves from the competition through our science and our innovative solutions, implement additional initiatives to unlock value, and gain additional share of our clients’ drug development and manufacturing programs. This focus on our strategy and our science positions us extremely well to lead the industry through advances in drug development,” Foster concluded.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River reports Q3 EPS $2.43, consensus $2.34
- Charles River Laboratories Intl (CRL) Q3 Earnings Cheat Sheet
- Charles River enters ADC drug discovery pact with Francis Crick Institute
- Charles River enters strategic collaboration with X-Chem
- Charles River price target raised to $174 from $155 at Mizuho